Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia
SEOUL, South Korea, Oct. 15 /PRNewswire/ -- Dong-A PharmTech Co. Ltd announced today the signing of a five-year US$50 Million contract with Otechestvennye Lekarstva OJSC, to market in Russia Dong-A's erectile dysfunction drug which is currently sold in Korea under the brand name of Zydena. Un...Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008
...th the prior year quarter. Included in R&D in the quarter ended December 31, 2008 was a $2.0 million expense to acquire certain rights from Dong-A pharmtech Co. Ltd. to develop and market its orally-administered udenafil product for the treatment of erectile dysfunction ("ED"). Excluding this $2.0 million ...Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
...ILTON, Bermuda, Jan. 6 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX ) today announced that it has signed an agreement with Dong-A pharmtech Co. Ltd., based in Korea, to develop and market their orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatm...Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
SEOUL, South Korea, Feb. 25 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that its European licensee, Dr. Falk Pharma, has initiated a 200 patient, phase 2 proof of concept clinical study to investigate the use of udenafil, a long acting phosphodiesterase type 5 inhibitor, for por...